Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461486 | 1.00 | ADORA3 (0.73) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL2461484 | 1.00 | ADORA3 (0.73) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL18089839 | 1.00 | ADORA3 (0.73) | ADORA3LMNANT5EHIF1AADORA2A | |
| Phosphoric Acid SCHEMBL2020883 | 0.95 | P2RY1 (0.73) | ADORA3LMNA | |
| Phosphoric Acid SCHEMBL3490778 | 0.95 | P2RY1 (0.73) | ADORA3LMNA | |
| Pyrophosphoric Acid SCHEMBL3227391 | 0.91 | P2RY1 (0.79) | LMNA | |
| SCHEMBL2458421 | 0.89 | ADORA3 (0.79) | ADORA3ADORA2AADORA2B | |
| SCHEMBL2458424 | 0.89 | ADORA3 (0.79) | ADORA3ADORA2AADORA2B | |
| SCHEMBL8862429 | 0.88 | ADORA3 (0.69) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL8862426 | 0.88 | ADORA3 (0.69) | ADORA3LMNANT5EHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2410332-A1 | Method for identifying purinergic modulators of the olfactory system | The University Of Utah (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100256086-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVETRSITY (IL) | 2010-10-07 | — | — | US | disclosed |
| US-20100256086-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVETRSITY (IL) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256086-A1 | NON-HYDROLYZABLE NUCLEOSIDE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | P2RY2, P2RY1, CCR2 | ADORA3 35/4885LMNA 3486/4885NT5E 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.